ARTICLE SUMMARY:
The recent news that Amber Therapeutics raised a spectacularly large Series A round was, for many medical device observers, a bolt out of the blue. But since its 2021 founding, the company has moved swiftly to assemble the necessary components to create a novel neuromodulation solution for urinary incontinence, which, underreported, underdiagnosed, and undertreated, affects over 60% of women.
Many observers of the medical device industry were surprised when, in early June, Amber Therapeutics (London, UK) raised a $100 million Series A round, a surprisingly large round for a medical device company developing an implantable device, and, as the press release claimed, one of the largest Series A rounds ever for a European device company. This is all the more surprising since the company is operating in an undervalued sector, women’s health, specifically, urinary incontinence (UI). Moreover, the little-known company pulled in high-quality healthcare investors—just the sort to support an early-stage medical device company in important ways during its journey. The round was led by New Enterprise Associates, with the participation of F-Prime Capital, Lightstone Ventures, and Intuitive Ventures. Existing investors Oxford Science Enterprises and 8VC participated in the large venture round.
